Schaefer K, von Herrath D, Erley C M
St. Joseph-Krankenhaus I, Medizinische Abteilung II, Berlin.
Am J Nephrol. 1988;8(3):173-8. doi: 10.1159/000167578.
Aluminum-containing phosphate binders have been widely employed in the past in the management of uremic hyperphosphatemia. However, an increasing number of reports on aluminum toxicity has stimulated efforts to replace this therapy by safer methods. The aim of the present review is to critically evaluate other treatment strategies. It appears that aluminum-containing phosphate binders should no longer be considered the treatment of choice for controlling uremic hyperphosphatemia. Calcium carbonate, calcium citrate, magnesium carbonate and a mixture of ketoanalogues and amino acids present important therapeutical alternatives which could replace aluminum-containing phosphate binders in the majority of patients. However, it is mandatory, as these therapies also carry some risks, that side effects are detected early.
含铝磷酸盐结合剂过去已被广泛用于治疗尿毒症高磷血症。然而，越来越多关于铝毒性的报告促使人们努力用更安全的方法取代这种治疗方法。本综述的目的是批判性地评估其他治疗策略。含铝磷酸盐结合剂似乎不应再被视为控制尿毒症高磷血症的首选治疗方法。碳酸钙、柠檬酸钙、碳酸镁以及酮类似物和氨基酸的混合物是重要的治疗替代方案，在大多数患者中可以取代含铝磷酸盐结合剂。然而，由于这些疗法也有一些风险，必须尽早发现副作用。
